title: [Prophylaxis of superficial bladder tumor with the intravesical instillation of bacillus Calmette-Guerin or anti-cancer agents. A retrospective study].
abstract: It was retrospectively analyzed whether intravesical instillation of bacillus Calmette-Guerin (BCG) or anti-cancer agents had prophylactic effect or not after removal of superficial bladder tumors. The results over a follow-up period ranging from 6 to 40 months showed 23.8 per cent recurrence in group 1 patients treated with BCG (21 patients), 46.7 per cent recurrence in group 2 treated with anti-cancer agents (45 patients) and 52.3 per cent recurrence in the group 3 (127 patients) which were not received any intravesical drugs. Long-term results among the 3 groups calculated with Kaplan-Meier method demonstrated that the instillation of BCG or of anti-cancer agents was more useful for prophylaxis, compared with the actuarial non-recurrence rates of group 3. The instillation of BCG showed good prophylactic effects especially in recurrent, grade 2 and pTa bladder tumors. The instillation of anti-cancer agents showed to provide prolonged protection from recurrence, but the instillation of BCG did not.
authors.affiliation: Department of Urology, Dokkyo University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: E
authors.initials: E
authors.lastname: Takasaki
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: K
authors.initials: K
authors.lastname: Kaneko
authors.forename: K
authors.initials: K
authors.lastname: Kanbe
authors.forename: S
authors.initials: S
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Mukae
authors.forename: Y
authors.initials: Y
authors.lastname: Hosoya
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: C C
authors.initials: CC
authors.lastname: Tseng
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine